It's striking--bordering on shocking--how investors have reacted differently to the megamergers by Pfizer and Merck, Motley Fool says. Merck traded down right after the announcement, but investors have bid up the stock by 17 percent since Merck announced it would by Schering; conversely, Pfizer's shares are down 18.3 percent. Report
Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product
Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.